On November 17, Medis successfully launched Celecoxib in Germany and France on Day-1 of patent expiry for its customers. Our customers were among the first to launch a total volume of 4.4 million tablets into their markets
Celecoxib is a COX-2 inhibitor which is a class of nonsteroidal anti-inflammatory drug (NSAID) that works by reducing hormones that cause inflammation and pain in the body. Celecoxib is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing, spondylitis (arthritis that mainly affects the spine), menstrual pain and acute pain.
During the complex launch process our teams encountered numerous obstacles in various fields, including on the manufacturing and regulatory sides of the process. We managed to solve these issues together with our resourceful counterparts in a combined effort to deliver a hugely successful launch.